The druggable genome and support for target identification and validation in drug development

Target identification (determining the correct drug targets for a disease) and target validation (demonstrating an effect of target perturbation on disease biomarkers and disease end points) are important steps in drug development. Clinically relevant associations of variants in genes encoding drug targets model the effect of modifying the same targets pharmacologically. To delineate drug development (including repurposing) opportunities arising from this paradigm, we connected complex disease- and biomarker-associated loci from genome-wide association studies to an updated set of genes encoding druggable human proteins, to agents with bioactivity against these targets, and, where there were licensed drugs, to…

• EL
  Eli Lilly and Company
• A
  AstraZeneca
• G
  GlaxoSmithKline
• S
  Sanofi
• W
  Wellcome

  Awards: WT104104/Z/14/Z, WT086151/Z/08/Z
• BH
  British Heart Foundation

  Award: PG12/71/29684
• UC
  University College London Hospitals NHS Foundation Trust